Literature DB >> 10688829

Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase.

L M O'Brien1, M Mastri, P J Fay.   

Abstract

Factor VIIIa is a trimer of A1, A2, and A3-C1-C2 subunits. Inactivation of the cofactor by human activated protein C (APC) results from preferential cleavage at Arg336 within the A1 subunit, followed by cleavage at Arg562 bisecting the A2 subunit. In the presence of human protein S, the rate of APC-dependent factor VIIIa inactivation increased several-fold and correlated with an increased rate of cleavage at Arg562. (Active site-modified) factor IXa, blocked cleavage at the A2 site. However, APC-catalyzed inactivation of factor VIIIa proceeded at a similar rate independent of factor IXa, consistent with the location of the preferential cleavage site within the A1 subunit. Addition of protein S failed to increase the rate of cleavage at the A2 site when factor IXa was present. In the presence of factor X, cofactor inactivation was inhibited, due to a reduced rate of cleavage at Arg336. However, inclusion of protein S restored near original rates of factor VIIIa inactivation and cleavage at the A1 site, thus overcoming the factor X-dependent protective effect. These results suggest that in the human system, protein S stimulates APC-catalyzed factor VIIIa inactivation by facilitating cleavage of A2 subunit (an effect retarded in the presence of factor IXa), as well as abrogating protective interactions of the cofactor with factor X. (Blood. 2000;95:1714-1720)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688829

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor.

Authors:  M Riewald; W Ruf
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

2.  Gly197Arg mutation in protein C causes recurrent thrombosis in a heterozygous carrier.

Authors:  Yeling Lu; Hemant Giri; Bruno O Villoutreix; Qiulan Ding; Xuefeng Wang; Alireza R Rezaie
Journal:  J Thromb Haemost       Date:  2020-04-09       Impact factor: 5.824

3.  Platelet protein S directly inhibits procoagulant activity on platelets and microparticles.

Authors:  Fabian Stavenuiter; Nicole F Davis; Erning Duan; Andrew J Gale; Mary J Heeb
Journal:  Thromb Haemost       Date:  2012-12-13       Impact factor: 5.249

Review 4.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.

Authors:  E A M Bouwens; F Stavenuiter; L O Mosnier
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

5.  Inhibition of thrombin formation by active site mutated (S360A) activated protein C.

Authors:  Gerry A F Nicolaes; Paul E Bock; Kenneth Segers; Karin C A A Wildhagen; Björn Dahlbäck; Jan Rosing
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

6.  Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.

Authors:  B Boylan; A S Rice; C De Staercke; M E Eyster; H M Yaish; C M Knoll; C J Bean; C H Miller
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

Review 7.  Regulation of the protein C anticoagulant and antiinflammatory pathways.

Authors:  A R Rezaie
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

8.  Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site.

Authors:  Masahiro Takeyama; Hironao Wakabayashi; Philip J Fay
Journal:  Thromb Haemost       Date:  2012-12-06       Impact factor: 5.249

9.  Down-regulation of the clotting cascade by the protein C pathway.

Authors:  Fabian Stavenuiter; Eveline A M Bouwens; Laurent O Mosnier
Journal:  Hematol Educ       Date:  2013

10.  Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.

Authors:  Tilman M Hackeng; Kristin M Seré; Guido Tans; Jan Rosing
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.